argenx SE (ETR:1AE)
Germany · Delayed Price · Currency is EUR | Market Cap | 50.99B +35.0% |
| Revenue (ttm) | 4.65B +70.3% |
| Net Income | 1.50B +33.9% |
| EPS | 22.95 +39.8% |
| Shares Out | n/a |
| PE Ratio | 33.97 |
| Forward PE | 32.37 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 98 |
| Open | 833.60 |
| Previous Close | 841.20 |
| Day's Range | 815.60 - 835.60 |
| 52-Week Range | 574.20 - 922.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 22, 2026 |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, system... [Read more]
Financial Performance
In 2025, argenx SE's revenue was $4.24 billion, an increase of 88.44% compared to the previous year's $2.25 billion. Earnings were $1.29 billion, an increase of 55.10%.
Financial numbers in USD Financial StatementsNews
Argenx To Present New VYVGART Data Across Autoimmune Neuromuscular Disorder At AANEM & MGF Session
(RTTNews) - On Tuesday, Argenx SE (ARGX) announced that it will present new clinical, long-term and real-world data for VYVGART (efgartigimod) across Myasthenia gravis and Chronic inflammatory demyeli...
Argenx to present new data across its portfolio, pipeline at 2026 AANEM
argenx (ARGX) will present new data from across its portfolio and pipeline at the 2026 American Association of Neuromuscular & Electrodiagnostic Medicine, AANEM, Annual Meeting and the Myasthenia Grav...
argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
New data show deepening improvement in ocular MG and sustained one-year efficacy in anti-AChR antibody-negative MG – broadening VYVGART's potential to treat all MG patients Real-world evidence from mo...
Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
BOSTON--(BUSINESS WIRE)--Ginkgo Datapoints and Apheris welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium.
Here's Exactly Why Wall Street Thinks Argenx Stock Could Soar 23% Over the Next 12 Months
Argenx's Vyvgart franchise enjoys strong sales momentum. The company has multiple registrational data read-outs on the way.
2 Wall Street Analysts Think Argenx Can Soar More Than 40%. Here's Why They're Right.
Wells Fargo and UBS have 12-month price targets for Argenx that are more than 40% above the current share price. Argenx's momentum and clinical successes appear to justify these lofty expectations.
argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
September 17, 2026 – 22:01PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced the results of the Extraordinary General Meet...
argenx SE at Morgan Stanley Global Healthcare Conference Transcript
argenx SE at Morgan Stanley Global Healthcare Conference Transcript
argenx SE Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
China innovation and AI integration are expanding opportunities, while MG and CIDP drive strong growth with new label expansions. The pipeline is robust, with key catalysts ahead in IMNM, MMN, and celiac, and a vision to reach 50,000 patients and 10 indications by 2030.
argenx SE Transcript: Wells Fargo 21st Annual Healthcare Conference
Vision 2030 targets treating 50,000 patients and 10 diseases, with strong progress in MG, CIDP, and pipeline expansion. VYVGART leads in MG and CIDP, while empasiprubart and FB102 target white space indications. Next-gen FcRn and a broad immunology focus support long-term growth.
BenchSci Announces Two-Year Enterprise Agreement with argenx to Advance AI-Driven Preclinical Drug Discovery
TORONTO--(BUSINESS WIRE)--BenchSci, a leading provider of AI software for biopharma research and development, today announced a two-year enterprise agreement with argenx, a global immunology innovatio...
Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated?
Argenx's top and bottom lines are growing robustly. The company expects to report multiple pivotal clinical results through the second half of 2027.
argenx to Present at Upcoming Investor Conferences
September 1, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that members of the management team will participate in the fol...
Argenx price target raised to $1,250 from $1,230 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Argenx (ARGX) to $1,250 from $1,230 and keeps an Overweight rating on the shares. The question is “no longer whether argenx can…
argenx Completes Acquisition of Forte Biosciences, Inc.
Acquisition adds first-in-class anti-CD122 Antibody, FB102, to argenx's immunology pipeline August 27, 2026 – 8:50 AM ET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunol...
Argenx price target raised to $1,415 from $1,350 at Wells Fargo
Wells Fargo analyst Derek Archila raised the firm’s price target on Argenx (ARGX) to $1,415 from $1,350 and keeps an Overweight rating on the shares. The firm says Argenx is…
Argenx Just Landed Another Phase 3 Win -- and Wall Street May Be Missing the Bigger Story
Argenx recently announced Phase 3 results for Vyvgart Hytrulo in treating autoimmune myositis. While there was one disappointment with the clinical study, the results were positive overall.
Argenx upgraded to Buy from Neutral at UBS
UBS analyst Xian Deng upgraded Argenx (ARGX) to Buy from Neutral with a price target of $1,400, up from $960. The firm views Vyvgart as a potential $20B drug, “and…
Argenx downgraded to Hold at Deutsche Bank after almost 50% advance
As previously reported, Deutsche Bank analyst Emmanuel Papadakis downgraded Argenx (ARGX) to Hold from Buy with a price target of EUR 925, up from EUR 900. The firm, which “modestly”…
Argenx downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank downgraded Argenx (ARGX) to Hold from Buy with a price target of EUR 925, up from EUR 900.
Argenx price target raised to $1,230 from $1,200 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Argenx (ARGX) to $1,230 from $1,200 and keeps an Overweight rating on the shares.
Argenx price target raised to $1,100 from $1,025 at RBC Capital
RBC Capital raised the firm’s price target on Argenx (ARGX) to $1,100 from $1,025 and keeps an Outperform rating on the shares after the company’s positive phase 3 top-line results…
Argenx price target raised to $1,150 from $1,050 at Wedbush
Wedbush raised the firm’s price target on Argenx (ARGX) to $1,150 from $1,050 and keeps an Outperform rating on the shares. The firm notes the company reported positive topline Phase…
Argenx price target raised to $1,100 from $1,037 at Oppenheimer
Oppenheimer raised the firm’s price target on Argenx (ARGX) to $1,100 from $1,037 and keeps an Outperform rating on the shares. The firm notes the company announced positive topline results…
Argenx price target raised to $1,095 from $1,030 at Truist
Truist analyst Danielle Brill raised the firm’s price target on Argenx (ARGX) to $1,095 from $1,030 and keeps a Buy rating on the shares. The firm is boosting its price…